1. Home
  2. BPYPO vs GNLX Comparison

BPYPO vs GNLX Comparison

Compare BPYPO & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BPYPO
  • GNLX
  • Stock Information
  • Founded
  • BPYPO N/A
  • GNLX 2001
  • Country
  • BPYPO Bermuda
  • GNLX United States
  • Employees
  • BPYPO 30200
  • GNLX N/A
  • Industry
  • BPYPO Real Estate
  • GNLX Biotechnology: Pharmaceutical Preparations
  • Sector
  • BPYPO Finance
  • GNLX Health Care
  • Exchange
  • BPYPO Nasdaq
  • GNLX Nasdaq
  • Market Cap
  • BPYPO N/A
  • GNLX 107.1M
  • IPO Year
  • BPYPO N/A
  • GNLX 2023
  • Fundamental
  • Price
  • BPYPO $16.27
  • GNLX $3.07
  • Analyst Decision
  • BPYPO
  • GNLX Strong Buy
  • Analyst Count
  • BPYPO 0
  • GNLX 4
  • Target Price
  • BPYPO N/A
  • GNLX $18.75
  • AVG Volume (30 Days)
  • BPYPO N/A
  • GNLX 172.0K
  • Earning Date
  • BPYPO N/A
  • GNLX 11-12-2024
  • Dividend Yield
  • BPYPO N/A
  • GNLX N/A
  • EPS Growth
  • BPYPO N/A
  • GNLX N/A
  • EPS
  • BPYPO N/A
  • GNLX N/A
  • Revenue
  • BPYPO N/A
  • GNLX $8,000.00
  • Revenue This Year
  • BPYPO N/A
  • GNLX N/A
  • Revenue Next Year
  • BPYPO N/A
  • GNLX N/A
  • P/E Ratio
  • BPYPO N/A
  • GNLX N/A
  • Revenue Growth
  • BPYPO N/A
  • GNLX N/A
  • 52 Week Low
  • BPYPO N/A
  • GNLX $1.60
  • 52 Week High
  • BPYPO N/A
  • GNLX $17.48
  • Technical
  • Relative Strength Index (RSI)
  • BPYPO 51.37
  • GNLX 59.37
  • Support Level
  • BPYPO $15.88
  • GNLX $2.98
  • Resistance Level
  • BPYPO $16.71
  • GNLX $3.50
  • Average True Range (ATR)
  • BPYPO 0.22
  • GNLX 0.31
  • MACD
  • BPYPO -0.14
  • GNLX 0.04
  • Stochastic Oscillator
  • BPYPO 33.97
  • GNLX 55.50

About BPYPO Brookfield Property Partners L.P.

Brookfield Property Partners LP owns, operates, and invests in commercial properties in North America, Europe, Australia, and Brazil. The company focuses on being an owner and operator of real estate, providing investors with diversified exposure to some of the iconic properties and acquiring high-quality assets at a discount to replacement cost or intrinsic value. Its operating segment includes Core Office, Core Retail, LP Investments, and Corporate Segments. The company operates in various sectors such as the office sector, retail sector, industrial, multifamily, hospitality, triple net lease, and corporate sector. It generates a majority of revenue from the LP Investments segment.

About GNLX Genelux Corporation

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.

Share on Social Networks: